NCT05357911View on ClinicalTrials.gov

A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

July 13, 2021

Primary Completion Date

August 20, 2021

Study Completion Date

December 3, 2021

Conditions

Solid Tumor

Interventions

DRUG

AB-106, digoxin

Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

Sponsors

Lead Sponsor

Nuvation Bio Inc.

Collaborators (1)

AnHeart Therapeutics Inc.

All Listed Sponsors

collaborator

AnHeart Therapeutics Inc.

INDUSTRY

lead

Nuvation Bio Inc.

INDUSTRY